/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/cpg/,/clinical/cckm-tools/content/cpg/hematology-and-coagulation/,/clinical/cckm-tools/content/cpg/hematology-and-coagulation/related/,

/clinical/cckm-tools/content/cpg/hematology-and-coagulation/related/name-97529-en.cckm

201704102

page

100

UWHC,UWMF,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Clinical Practice Guidelines,Hematology and Coagulation,Related

Appendix D. VTE Risk Assessment - Orthopedic - Adult - Inpatient

Appendix D. VTE Risk Assessment - Orthopedic - Adult - Inpatient - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Clinical Practice Guidelines, Hematology and Coagulation, Related


Appendix E. VTE Risk in the Surgical Orthopedic Patient – Adult – Inpatient – Venous
Thromboembolism (VTE) Prophylaxis – CPG
Orthopedic VTE Risk Assessment
Elevated VTE risk*
ξ Cancer (current or previous history)
ξ Previous DVT or PE
ξ Hypercoagulable state
ξ Multiple trauma
ξ Spinal cord injury
* VTE risk assessments in the orthopedic population have not been validated. Surgery specific VTE risk
should outweigh a patient’s contributing individual risk. Above are additional patient-specific risk factors
for VTE that may be considered.
VTE prophylaxis recommendations based on risk
For moderate VTE risk one of the below should be selected (bolded preferred)
ξ Enoxaparin 40 mg subcutaneous every 24 hours
ξ Warfarin
ξ Aspirin
ξ Mechanical prophylaxis
For high VTE risk a pharmacologic agent AND mechanical agent should be selected (bolded
preferred)
ξ Enoxaparin 40 mg subcutaneous every 24 hours
ξ Warfarin
ξ Aspirin
ξ Mechanical prophylaxis
CPG Contact for Changes:
Name: Philip J Trapskin, PharmD, BCPS
Phone Number: 263-1328
Email Address: ptrapskin@uwhealth.org
Revised: 12/2016
Copyright © 2017 Univ ersity of Wisconsin Hospital s and Clinics Authority
Contact: Lee Vermeulen, CCKM @uwhealth.org Last Revised: 04/2017CCKM@uwhealth.org